Through a new approach dubbed AMBAR, the biotechnology company Grifols has attempted to reduce the amount of harmful, Alzheimer’s disease-causing amyloid beta in the brain by collecting it with a blood protein called albumin and draining it out of the bloodstream. This approach differs from the previous antibody and catabody approaches and offers new hope…

Earlier this year, we hosted the Ending Age-Related Diseases 2018 conference at the Cooper Union in New York City. This conference was designed to bring together the best in the aging research and biotech investment worlds and saw a range of industry experts sharing their insights. Dr. Sudhir Paul from Covalent Bioscience talks about his…

Today, we are going to be taking a look at GAIM and what it might mean for treating amyloid-based diseases, such as Alzheimer’s, Parkinson’s, and amyloidosis. This approach has the potential to treat multiple age-related diseases at once by targeting a common characteristic that they all share. Misfolded proteins cause multiple age-related diseases Proteins are…

Vascular risk appears to be a strong predictor of dementia, especially in older individuals with high levels of brain beta-amyloids, and the interaction between these two risk factors might lead to a higher rate of cognitive decline, according to a recent study at the Massachusetts General Hospital. Alzheimer’s disease (AD) is an age-related neurological disorder…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD